Praxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $130.00 at Wedbush

Praxis Precision Medicines (NASDAQ:PRAX) had its price target lifted by Wedbush from $95.00 to $130.00 in a research note released on Friday, Marketbeat.com reports. Wedbush currently has an underperform rating on the stock.

Several other research firms have also commented on PRAX. UBS Group set a $750.00 target price on shares of Praxis Precision Medicines in a research note on Monday, December 15th. Truist Financial upped their price target on Praxis Precision Medicines from $360.00 to $500.00 and gave the company a “buy” rating in a report on Monday, December 8th. Guggenheim reissued a “buy” rating and set a $800.00 price objective (up from $760.00) on shares of Praxis Precision Medicines in a research note on Tuesday, February 10th. Jefferies Financial Group restated a “buy” rating and issued a $450.00 target price (up from $300.00) on shares of Praxis Precision Medicines in a report on Tuesday, December 9th. Finally, Wells Fargo & Company set a $305.00 target price on Praxis Precision Medicines and gave the company an “equal weight” rating in a report on Friday. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $580.88.

Praxis Precision Medicines Stock Up 1.1%

Shares of Praxis Precision Medicines stock opened at $335.28 on Friday. The business has a fifty day simple moving average of $300.60 and a 200-day simple moving average of $178.26. Praxis Precision Medicines has a fifty-two week low of $26.70 and a fifty-two week high of $349.32. The firm has a market cap of $8.45 billion, a price-to-earnings ratio of -24.91 and a beta of 2.84.

Praxis Precision Medicines (NASDAQ:PRAX) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($3.50) EPS for the quarter, missing the consensus estimate of ($3.00) by ($0.50). Analysts anticipate that Praxis Precision Medicines will post -10.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC lifted its stake in Praxis Precision Medicines by 17.2% in the 4th quarter. Janus Henderson Group PLC now owns 3,240,086 shares of the company’s stock worth $954,834,000 after acquiring an additional 476,227 shares in the last quarter. Perceptive Advisors LLC increased its holdings in shares of Praxis Precision Medicines by 27.6% in the 4th quarter. Perceptive Advisors LLC now owns 1,995,986 shares of the company’s stock valued at $588,297,000 after purchasing an additional 431,432 shares during the period. Adage Capital Partners GP L.L.C. increased its holdings in shares of Praxis Precision Medicines by 13.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,974,585 shares of the company’s stock valued at $83,031,000 after purchasing an additional 231,827 shares during the period. Vanguard Group Inc. lifted its position in shares of Praxis Precision Medicines by 15.3% in the fourth quarter. Vanguard Group Inc. now owns 1,460,933 shares of the company’s stock worth $430,595,000 after purchasing an additional 193,647 shares in the last quarter. Finally, Orbis Allan Gray Ltd acquired a new stake in shares of Praxis Precision Medicines during the fourth quarter worth approximately $369,946,000. Hedge funds and other institutional investors own 67.84% of the company’s stock.

Praxis Precision Medicines News Roundup

Here are the key news stories impacting Praxis Precision Medicines this week:

• Positive Sentiment: Company filed two NDAs — Praxis submitted NDAs to the FDA for ulixacaltamide (essential tremor) and relutrigine (SCN2A/SCN8A DEEs), a major regulatory milestone that materially de-risks timing to potential approvals and commercial launch. GlobeNewswire: Corporate Update & 2025 Results
• Positive Sentiment: Strong analyst bullishness — Truist raised its price target to $700 and kept a Buy rating, signaling confidence in commercial potential (large upside vs. current levels); other firms (e.g., Guggenheim) have also raised targets into the high hundreds. These upgrades support demand from growth-oriented investors. The Fly: Truist PT Raise
• Neutral Sentiment: Analyst confidence narratives — Several write-ups highlight ulixacaltamide as the valuation driver and list large addressable markets; these pieces buoy sentiment but are forward-looking and hinge on FDA review/outcomes. Yahoo Finance: Analyst Confidence
• Neutral Sentiment: Corporate update and earnings call — Management provided Q4/2025 results and a corporate update; call highlights and the company’s pipeline/regulatory timeline were reviewed, which investors parsed for approval timelines and cash runway. Yahoo Finance: Q4 Call Highlights
• Negative Sentiment: Q4 earnings miss — Praxis reported EPS of ($3.50), missing consensus (~($3.00)), which can pressure the stock by highlighting higher near-term spend and delays to profitability despite pipeline progress. MarketBeat: Q4 EPS Miss
• Negative Sentiment: Mixed / cautious research — Wedbush raised its PT but kept an Underperform rating (PT $130), and Wells Fargo initiated with an Equal Weight/$282 PT, underscoring that some analysts see valuation/near-term execution risk despite regulatory progress. Those views can create selling pressure from more conservative holders. The Fly: Wedbush PT & Rating

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.